Doorgaan naar hoofdcontent

bioMérieux SA, FSN-FSCA 5230, ETEST®IMIPENEM RELEBACTAM-WW & US

 

 
 
bioMérieux SA, FSN-FSCA 5230, ETEST®IMIPENEM RELEBACTAM-WW & US
This letter is intended for all ETEST® Imipenem/Relebactam (IPR) (Ref: 420925 & 420927) users.



 
 
Human medicines European public assessment report (EPAR): Ozurdex, dexamethasone, Macular Edema,Uveitis, Date of authorisation: 26/07/2010, Revision: 16, Status: Authorised
Human medicines European public assessment report (EPAR): Ozurdex, dexamethasone, Macular Edema,Uveitis, Date of authorisation: 26/07/2010, Revision: 16, Status: Authorised



 
 
Human medicines European public assessment report (EPAR): Pemetrexed Lilly, pemetrexed, Carcinoma, Non-Small-Cell Lung,Mesothelioma, Date of authorisation: 14/09/2015, Revision: 6, Status: Authorised
Human medicines European public assessment report (EPAR): Pemetrexed Lilly, pemetrexed, Carcinoma, Non-Small-Cell Lung,Mesothelioma, Date of authorisation: 14/09/2015, Revision: 6, Status: Authorised


Actueel zorgnieuws in jouw mailbox ontvangen?
Direct het hele artikel lezen? Meld je aan voor de nieuwsbrief.